QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Why Quidel Corp (QDEL) Might Surprise This Earnings Season
by Zacks Equity Research
Quidel Corp (QDEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 30%+ to over $335 million on COVID-19 testing and its mutations
Quidel (QDEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $236.38, moving +1.5% from the previous trading session.
Why Quidel (QDEL) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed a recovery in rapid immunoassay revenues during Q4.
Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed at $236.85 in the latest trading session, marking a +1.29% move from the prior day.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Quidel (QDEL) Stock Moves -0.87%: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed at $224.21 in the latest trading session, marking a -0.87% move from the prior day.
QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise
by Zacks Equity Research
QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.
Top Ranked Growth Stocks to Buy for January 25th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 25th
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
Integra (IART) Acquires Acell, Focuses on Regenerative Space
by Zacks Equity Research
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays
by Zacks Equity Research
Globus Medical's (GMED) recent product launches are seeing tremendous uptake.
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
by Zacks Equity Research
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing
by Zacks Equity Research
PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.
4 Momentum Stocks to Explore the Lucrative Driehaus Strategy
by Nitish Marwah
Investors who have the propensity to take a higher risk can think of investing in momentum stocks to boost their gains.
Quidel (QDEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $198.03, moving +0.05% from the previous trading session.
3 Reasons Why Growth Investors Shouldn't Overlook Quidel (QDEL)
by Zacks Equity Research
Quidel (QDEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
QDEL vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. RMD: Which Stock Is the Better Value Option?
Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+
by Zacks Equity Research
Neogen's (NEOG) new test can detect cancer causing aflatoxin M1 in milk within a range of 150-600 parts per trillion (ppt).
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax
by Zacks Equity Research
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.